BriaCell Therapeutics Corp.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-26.3M | $-4.8M | $-20.3M | $-26.8M | $-13.8M | $-4.0M |
| Depreciation & Amortization | — | — | — | $15.3K | $15.3K | — |
| Depreciation | $91.4K | $68.6K | — | — | — | — |
| Amortization | $15.3K | $15.3K | $15.3K | $15.3K | $15.3K | $15.3K |
| Stock-Based Compensation | $776.9K | $1.8M | $2.2M | $3.1M | $2.0M | $1.7K |
| Net Cash from Operating Activities | $-28.2M | $-24.1M | $-23.7M | $-12.5M | $-7.8M | $-1.3M |
| Investing Activities | ||||||
| Capital Expenditures | — | $456.8K | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-7.6M | $-681.8K | — | — | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $45.4M | $4.4M | $4.0M | $-3.7M | $65.0M | $1.2M |
| Net Change in Cash | $9.6M | $-20.4M | $-19.8M | — | $57.2M | $-91.8K |
| Free Cash Flow | — | $-24.6M | — | — | — | — |